- Home
- DTF vs STRO Comparison
DTF vs STRO Comparison
Compare DTF & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTF
- STRO
- Stock Information
- Founded
- DTF 1991
- STRO 2003
- Country
- DTF United States
- STRO United States
- Employees
- DTF N/A
- STRO N/A
- Industry
- DTF Investment Managers
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DTF Finance
- STRO Health Care
- Exchange
- DTF Nasdaq
- STRO Nasdaq
- Market Cap
- DTF 78.2M
- STRO 77.7M
- IPO Year
- DTF N/A
- STRO 2018
- Fundamental
- Price
- DTF $11.19
- STRO $0.91
- Analyst Decision
- DTF
- STRO Hold
- Analyst Count
- DTF 0
- STRO 7
- Target Price
- DTF N/A
- STRO $5.47
- AVG Volume (30 Days)
- DTF 21.1K
- STRO 1.1M
- Earning Date
- DTF 01-01-0001
- STRO 05-08-2025
- Dividend Yield
- DTF 3.64%
- STRO N/A
- EPS Growth
- DTF N/A
- STRO N/A
- EPS
- DTF 0.44
- STRO N/A
- Revenue
- DTF N/A
- STRO $66,434,000.00
- Revenue This Year
- DTF N/A
- STRO N/A
- Revenue Next Year
- DTF N/A
- STRO N/A
- P/E Ratio
- DTF $24.34
- STRO N/A
- Revenue Growth
- DTF N/A
- STRO N/A
- 52 Week Low
- DTF $10.29
- STRO $0.52
- 52 Week High
- DTF $11.19
- STRO $5.17
- Technical
- Relative Strength Index (RSI)
- DTF 52.43
- STRO 51.49
- Support Level
- DTF $11.14
- STRO $0.86
- Resistance Level
- DTF $11.21
- STRO $0.99
- Average True Range (ATR)
- DTF 0.05
- STRO 0.08
- MACD
- DTF 0.00
- STRO 0.00
- Stochastic Oscillator
- DTF 55.00
- STRO 71.59
About DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing primarily in a diversified portfolio of investment-grade tax-exempt obligations.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.